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Abstract
In order to study oxidative stress in peripheral cells of Alzheimer’s disease (AD) patients, immortalized lymphocytes derived
from two peculiar cohorts of patients, referring to early onset AD (EOSAD) and subjects harboured AD related mutation
(ADmut), were used. Oxidative stress was evaluated measuring i) the typical oxidative markers, such as HNE Michel adducts,
3 Nitro-Tyrosine residues and protein carbonyl on protein extracts, ii) and the antioxidant capacity, following the enzymatic
kinetic of superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione reductase (GRD). We found that the
signs of oxidative stress, measured as oxidative marker levels, were evident only in ADmut but not in EOSAD patients.
However, oxidative imbalance in EOSAD as well as ADmut lymphocytes was underlined by a reduced SOD activity and GRD
activity in both pathological groups in comparison with cells derived from healthy subjects. Furthermore, a redox
modulated p53 protein was found conformational altered in both EOSAD and ADmut B lymphocytes in comparison with
control cells. This conformational altered p53 isoform, named ‘‘unfolded p53’’, was recognized by the use of two specific
conformational anti-p53 antibodies. Immunoprecipitation experiments, performed with the monoclonal antibodies
PAb1620 (that recognizes p53wt) and PAb240 (that is direct towards unfolded p53), and followed by the immunoblotting
with anti-4-hydroxynonenal (HNE) and anti- 3-nitrotyrosine (3NT) antibodies, showed a preferential increase of nitrated
tyrosine residues in unfolded p53 isoform comparing to p53 wt protein, in both ADmut and EOSAD. In addition, a
correlation between unfolded p53 and SOD activity was further found. Thus this study suggests that ROS/RNS contributed
to change of p53 tertiary structure and that unfolded p53 can be considered as an early marker of oxidative imbalance in
these patients.
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Introduction
Generation of reactive oxygen species (ROS), that are an inevitable
by-product of cellular respiration, is believed to contribute substan-
tially to the aging process [1]. Further increased ROS, as the
consequence of pathological conditions as well as the exposure to
endogenous and exogenous compounds, are, in turn, responsible for
progressive decline in biological functions with time, and for higher
predisposition to age-related disease, such as cancer, cardiovascular
and neurodegenerative diseases [2,3]. Persistent high levels of ROS/
RNS can inflict direct damage to macromolecules, such as lipids,
nucleic acids and proteins [4], impairing their functions, with a
substantial physio-pathological impact [5]. The central nervous
system (CNS) is very prone to oxidative imbalance because it is very
rich of polyunsaturated fatty acids (PUFAs), has a high metabolic
oxidative rate and high content of transient metals and ascorbate
levels, which together act as pro-oxidant, but by contrast it possesses a
relative paucity of antioxidant system compared with other organs [6].
Alzheimer’s disease (AD) is the most frequent form of
neurodegenerative disease associated with dementia in the elderly.
Approximately 5% of AD is caused by mutations in the genes for
either Amyloid precursor protein (APP) or some of the enzymes
involved in its metabolism, Presenilin 1 and Presenilin 2 [7]. The
remaining 95% are sporadic cases, whose causes are still unclear.
Apart from the pathological hallmarks of the disease, which
include accumulation of protein deposits in the brain as Ab
plaques and neurofibrillary tangles, AD brain exhibits constant
evidence of ROS and RNS mediated injury [8]. Oxidative
markers, such as 4-hydroxynonenal and malondyaldehyde,
nitrotyrosine and protein carbonyls were found increased in post
mortem AD brain [9–12]. Furthermore, different animal models of
AD pathology, ei. Tg2576, APP23, APP/PS1 double knock-in,
and triple Tg-AD, manifested features of lipid and protein
oxidation at the early stage of their pathogenesis [13–15]. All
these data support the basis of the oxidative stress hypothesis of
AD.
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29789Starting by the point of view that AD is a systemic disease, the
oxidative imbalance, observed as oxidative damage in AD brain,
may occur also in peripheral tissues of AD patients. Based on this
concept, oxidative markers and the efficiency of antioxidant enzyme
activityhavebeeninvestigated inperipheraltissuesofADcomparing
them with those of healthy subjects [16]. The improvement in
studying peripheral tissue, ei blood cells, is undoubtedly the easy
accessibility of the biological sample on alive patient and the
possibility to follow himin his history of illness. However, data inthis
contest are not so clear and are often contradictory.
Thus the aim of this study was to well characterize oxidative
stress in AD taking advantage by the use of immortalized B
lymphocytes derived from two peculiar cohorts of AD patients:
patients harbouring AD-related mutation (ADmut) and sporadic
AD, who developed the disease very early, and for this reason
called Early Onset Sporadic Alzheimer’s Disease (EOSAD); and
comparing them with cells derived from healthy subjects.
Because our group previously demonstrated the expression of an
anomalous tertiary structure of p53 protein in different peripheral
cells derived from sporadic AD patients [17,18] and many
indications suggested p53 as a redox sensitive protein [19,20],
we also investigated whether a correlation between the expression
of this conformationally altered p53 (unfolded p53) and oxidative
profile in AD B lymphocytes exists.
Results
Oxidative profile in EOSAD and ADmut lymphocytes
Oxidative profile was evaluated measuring the expression of
oxidative markers and the activity and levels of antioxidant
enzymes in immortalized B lymphocytes derived from two peculiar
cohorts of AD patients: sporadic cases with an early onset
(EOSAD) and familial AD, named ADmut, because not all of
them developed AD yet at the moment of blood withdrawal.
4-hydroxy-2-nonenal (HNE), a product of lipid peroxidation
[21–23] which by Michael addiction is able to bind proteins, 3-
nitrotyrosine (3NT) [24,25], a product of protein nitration and
protein carbonyl (PC), derived from protein oxidation [26,27],
were measured using dot blot technique (Fig. 1). HNE adduct
product levels and 3NT levels were found significantly enhanced
in ADmut cells in comparison with control lymphocytes (mean
value 6 SEM: 1,1260.49 vs 0,6860,026; 1,860,12 vs 0,3860,02
for HNE and 3NT respectively) (Fig. 1 A, B). In EOSAD samples,
HNE adduct product (mean value 6 SEM: 0,8260,4) and 3NT
levels (mean value 6 SEM: 0,9560,38) were no statistically
different from controls. No statistically significant differences were
found examining PC levels in ADmut and EOSAD in comparison
with control cells (Fig. 1 C), probably due to the scatter of values
(mean value 6 SEM 0,4860,045; 1,260,13; 0,7860,07 for
control EOSAD, and ADmut respectively). On the other hand,
PC levels in ADmut were statistically significant in comparison
with control by using the Bartlett’s test for equal variances, but not
with one way ANOVA and the Bonferroni tests (Fig. 1 C).
Immortalized lymphocytes of the three groups were also
processed for the measurement of SOD1 and SOD2 levels by
western blot analysis and total SOD activity. In particular western
blot analysis of protein extracts derived from control, ADmut and
EOSAD lymphocytes were carried out with specific monoclonal
anti-SOD1 and anti-SOD2 antibodies and then tubulin expression
was used to normalize all samples. A representative experiment on
Figure 1. Oxidative profile in EOSAD, ADmut and control lymphocytes. Dot blot analysis on protein extracts derived from controls (n=9),
EOSAD (n=9) and ADmut (n=9) lymphocytes were performed using specific antibodies against oxidative stress markers: protein-bound HNE (A), 3NT
(B) and PC (C). Tubulin expression was used to normalize the samples. * p,0,05 control vs ADmut.
doi:10.1371/journal.pone.0029789.g001
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EOSAD is reported in Figure 2A. No difference in the expression
of SOD1 and SOD2 was found in those samples. This trend was
confirmed when the record of cases was increased, thus underlying
a similar expression of SOD1 and SOD2 in ADmut, EOSAD and
control lymphocytes (fig. 2B and C). SOD activity, measured as
unit of enzyme able to inhibit epinephrine oxidation, was found
lower in EOSAD and ADmut B lymphocytes in comparison with
control cells, being any way lowest in ADmut samples (SOD mU/
mg protein control: 0,06260,006; EOSAD: 0.041
*60.002
ADmut: 0.025
**60,004 *p,0,001 vs control **p,0,0001 vs
control) (fig. 2D).
The same samples were also processed for GPx and GRD
activity (fig. 3). No difference was found in the expression of GPx
activity (fig. 3 panel A) among the three groups of lymphocytes.
The values of GPx activity were highly scattered, especially in the
group of control and EOSAD, loosing statistically significant
differences. At variance, GRD activity was lower in EOSAD
(0,05060,006 vs control 0,0960,01, p,0,001) and ADmut
immortalized lymphocytes (0,0760,01 vs control 0,0960,01,
p,0,01) in comparison with control cells (fig. 3 panel B).
p53 conformational state in EOSAD, ADmut and control
lymphocytes
Taking advantage by the use of two conformational specific
anti-p53 antibodies, PAb1620 and PAb240, which discriminate
folded vs. unfolded p53 tertiary structure [28], p53 conformational
states were examined in immortalized lymphocytes derived from
EOSAD, ADmut and healthy subjects. The experiments foresaw
the immunoprecipitation with the two specific conformational
antibodies, PAb1620 and PAb240 followed by immunoblotting
with a rabbit polyclonal anti-p53 antibody. In particular PAb1620
binds to a denaturation-sensitive epitope within the DNA-binding
surface [29], whereas PAb240 recognizes a primary epitope that is
cryptic in the wild type conformation and becomes exposed when
the protein changes its conformation towards an unfolded
phenotype [30]. As showed in representative immunoprecipitation
experiments, lymphocytes derived from healthy subjects expressed
an intense band related to wild-type p53, as demonstrated by the
reactivity with PAb1620, while immunoreactivity to PAb240
(unfolded p53) was very low. Three representative EOSAD and
four ADmut cells (PS1P117R, APPT714A, PS1I123F and
PS1M139V) expressed, besides the PAb1620-positive p53 isoform,
a higher immunoreactivity to PAb240 (fig. 4 panel A, B). When an
increased number of EOSAD (n=9), ADmut (n=9) and control
(n=9) cell lines was tested for immunoprecipitation experiments,
two well separated p53 phenotype patterns were identified. The
ratio of PAb240/PAb1620 was statistically higher in EOSAD and
ADmut in comparison with control cells (Fig. 4 C). Furthermore,
to test whether altered p53 conformation, found in EOSAD and
ADmut lymphocytes, compromised p53 functionality, p53 tran-
scriptional activity was evaluated by luciferase assay of the
Figure 2. Expression of SOD1 and SOD2 protein levels and activity in ADmut, EOSAD and control lymphocytes. Protein extracts
derived from immortalized lymphocytes of ADmut, EOSAD and healthy individuals were prepared as reported in method section. A) Western blot
analysis carried out with monoclonal anti-SOD1 and anti-SOD2 antibodies on protein extracts derived from 2 controls, 2 ADmut, and 2 EOSAD.
Tubulin expression was used to normalize the samples. B) and C) SOD1 and SOD2 levels of 9 controls, 9 ADmut and 9 EOSAD were measured using
Scion Image program: quantitative analysis was expressed as intensity (optical density) of SOD1 or SOD2 bands over tubulin levels. D) enzymatic
activity of superoxide dismutase (SOD) measured in controls (n=9), EOSAD (n=9) and ADmut (n=9) lymphocytes using specific enzymatic assay (see
method section).
doi:10.1371/journal.pone.0029789.g002
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performed on cells derived from 1 control, 1 EOSAD and 3
ADmut (PS1H163R, PS2 Q228L and PS1M139V). Cells were
transiently transfected with the p53AIP1-luc reporter plasmid and
18 hrs later treated with 50 mM doxorubicin, a cytotoxic agent
able to induce DNA damage and apoptosis in a p53-dependent
manner [32]. As shown in Figure 4 panel D, p53AIP1-luciferase
activity was induced by doxorubicin treatment in cells from
control subject, whereas it was significantly impaired in EOSAD
and ADmut cells.
It is noteworthy that the value of unfolded p53 was well
correlated with SOD activity. Lower values of SOD were
associated with higher value of unfolded p53 in both pathological
and control cells (regression equation: y=2518 x+0,1973; r
2
0,2321; p=0,01) (fig. 5, A). At variance, the decrease of GR
activity did not correlate with unfolded p53 (data not shown). It is
Figure 3. The enzymatic activity of glutathione peroxidase (GPX) and glutathione reductase (GRD). A) glutathione peroxidase (GPX) was
measured in controls (n=9), EOSAD (n=9) and ADmut (n=9) lymphocytes using specific assay (see method section). B) glutathione reductase (GRD)
was measured in controls (n=9), EOSAD (n=9) and ADmut (n=9) lymphocytes using specific assay (see method section).
doi:10.1371/journal.pone.0029789.g003
Figure 4. p53 conformational state in EOSAD, ADmut and control lymphocytes. Protein extracts derived from control, ADmut and EOSAD
lymphocytes were immunoprecipitated by PAb240 (specific for p53 mutant isoform) and PAb1620 (specific for p53 wild-type isoform) antibodies.
Immunoprecipitates were analysed by Western blot with the CM1 polyclonal anti-p53 antibody. (A)&( B) Representative blots of data from ADmut
(n=4), EOSAD (n=3), and control (n=2) lymphocytes. Immunoprecipitated antibodies were omitted in control (blk) samples (C) Ratio between the
intensity of PAb240 and PAb1620 immunoreactive bands obtained from controls (n=9), EOSAD (n=9) and ADmut (n=9) lymphocytes. Bars
represent median value of the respective group. Data are expressed as mean 6 SEM. * p,0,001. (D) Cells from control, EOSAD and ADmut subjects
were transfected with p53AIP1-luc reporter construct and 18 h after transfection treated with doxorubicin (50 mM) for 24 h before luciferase activity
was assayed. Luciferase activity was expressed as % of relative luminescence unit (RLU%) and compared to control values (cells without doxorubicin)
assumed at 100%. Each bar represents the mean 6 SD of six independent experiments. Statistical analysis was performed with Bonferroni multiple
comparison test, with *** p,0.0001 vs CTR without doxorubicin.
doi:10.1371/journal.pone.0029789.g004
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subjects was exposed for 24 h with the SOD inhibitor,
diethyldithiocarbamic acid (DETC) at the concentration of
5 mM, a 50% decrease of SOD activity and a comparable
increase of PAb240 absorbance, indicative of unfolded p53
isoform, were observed, suggesting a strictly correlation between
SOD activity and p53 conformational state (fig. 5 B).
Oxidative modulation of p53 molecule in EOSAD and
ADmut lymphocytes
Besides germ line mutations, conformational changes in p53
protein can occur following post-transcriptional modifications
[28,33,34]. Numerous studies reported that cysteine oxidation
inside the DNA binding domain can affect the p53 conformational
status [20,35,36]. Oxidative modulation of p53 was assessed by
immunoprecipitating the protein with conformational specific
antibodies, and then blotting the membranes with anti-HNE and
anti-3NT antibodies. The data were normalized with the levels of
wild type and unfolded p53 respectively. Figure 6A shows a
representative experiment performed on one control, one ADmut
(PS1 P117R mutation) and one EOSAD. PS1 P117R mutated
lymphocytes showed increased levels of p53-bound HNE in
comparison with control. In particular HNE Michael adducts
were found in both wild type and unfolded p53 phenotypes.
However, when more samples were processed, no statistically
significant differences among ADmut, EOSAD and control
lymphocytes were observed in p53-bound HNE levels (mean
value 6 SEM; control cells: p53wt 0,6060,12, p53 unfolded
0,8260,09; ADmut lymphocytes p53wt 2,761,68 p53 unfolded
2,961,01; EOSAD p53wt 1,2860,85 p53 unfolded 2,861,05)
(Fig. 6B). The measurement of the amount of nitrated tyrosine
residues on p53 molecule showed a more intense band in the
samples immunoprecipitated with PAb240 antibody in compari-
son with those immunoprecipitated with PAb1620 (Fig. 6 C). In
both PS1P117R mutated and EOSAD cells unfolded p53 was
more nitrated than unfolded p53 of control cells (Fig. 6C). This
pattern was confirmed also in the other ADmut, EOSAD and
control samples examined. Figure 6D depicted the quantitative
analysis of p53-3NT levels over corresponding wild type and
unfolded p53 levels of 5 controls, 6 ADmut and 5 EOSAD cells.
The expression of p53-3NT was found statistically increased both
in EOSAD and ADmut lymphocytes in comparison with control
cells, when the protein was in an unfolded conformation,
recognized by PAb240 antibody (mean value 6 SEM: control
cells: p53wt 0,8660,18, p53 unfolded 1,0160,92; ADmut
lymphocytes p53wt 1,2860,60 p53 unfolded 3,8260,64; EOSAD
p53wt 0,8860,35 p53 unfolded 4,0060,95) (Fig. 6D). To give
more insight on the effects of tyrosine nitration on p53 tertiary
structure, lymphocytes derived from one healthy subject were
exposed to a peroxynitrite-generating compound, 3-morpholino-
Figure 5. (A)correlative analysis between SOD activity and unfolded p53 on all samples (control, EOSAD and FAD) considered in
this study. The equation of linear regression is y=25,518x+0,1973 r
2 0,2321 p=0,01. (B) lymphocytes derived from a healthy subject were exposed
to SOD inhibitor DETC (5 Mm) and 24 h later they were processed for SOD enzyme activity and the expression of PAb 240 -positive p53 isoform by
using ELISA assay. Data are expressed as mean 6 SEM of three different experiments, performed in triplicate. Statistical analysis was performed with t
test with * p,0,001, ** p,0,001 vs untreated samples.
doi:10.1371/journal.pone.0029789.g005
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e29789Figure 6. Oxidated/nitrated wild-type and mutant p53 in EOSAD, ADmut, and control lymphocytes. Representative blot of data
obtained from PS1P117R mut (n=1), EOSAD (n=1) and control (n=1) lymphocytes. Equal amount of protein from control, ADmut and EOSAD
lymphocytes were immunoprecipitated with conformation specific anti-p53 antibodies, and immunoprecipitates were analyzed for HNE (A) or 3NT
(B) immunoreactivity by Western blotting. (C) Graphical analysis of HNE-p53 band intensities of controls (n=5), EOSAD (n=5), and ADmut (n=6). p53
expression was used to normalize the intensity of each band. Bars represent median value of the respective group. Data are expressed as mean 6
SEM. (D) Graphical analysis of 3NT-p53 band intensities of controls (n=5), EOSAD (n=5) and ADmut (n=6). p53 expression was used to normalize the
intensity of each band. Bars represent median value of the respective group. Data are expressed as mean 6 SEM. * p,0,01.
doi:10.1371/journal.pone.0029789.g006
Figure 7. Effects of peroxynitrite compound SIN-1 on p53 conformation. Lymphocytes derive from a healthy subject were exposed to
500 mM SIN-1 in the presence or absence of uric acid at the same concentration. In particular SIN-1 was added 30 min after uric acid addition and
incubated for the next 4 hours. Cells were then processed for (A) RNS generation study by FACS analysis measuring DCF fluorescence; (B) Pab 240
positive p53 isoform (unfolded p53) measured by ELISA assay, and (C) the degree of p53 nitration on tyrosine residues investigated by
immunoprecipitation experiment with the two conformational specific antibodies (PAb 1620 and pab 240) followed by immunoblottin, with anti-
rabbit-anti-3NT or anti-goat anti-p53 (R19).
doi:10.1371/journal.pone.0029789.g007
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500 mM in the presence or absence of uric acid (500 mM), a
peroxynitrite scavenger [37]. Four hours later, FACS analysis
demonstrated increased RNS generation induced by SIN-1, that
was prevented by the co-exposure with uric acid, as shown by the
shift of DCF fluorescence (fig. 7A). Peroxynitrite-generating
compound increased also PAb240 absorbance in ELISA assay
and this effect was reverted by uric acid (fig. 7B). Finally,
immunoprecipitation experiments were performed using the two
specific conformational anti-p53 antibodies, PAb1620 and
PAb240, followed by immunoblotting with anti-3NT antibody or
anti-p53 antibody. As shown in figure 7C, SIN-1-induced tyrosine
nitration was responsible of p53 conformational changes towards
an unfolded phenotype. In particular, immunoprecipitated
samples derived from cells treated with SIN-1 showed, in addition
to a wt p53 isoform immunoreactive to PA1620, an intense
PAb240 positive band. While untreated cells especially expressed
wt p53 (PAb1620 positive p53 isoform). The co-exposure of SIN1
with uric acid prevented the increased expression of unfolded p53
immunoreactive to PAb240 (fig. 7C), even if the wt-p53 expression
was anyway intense, more than untreated cells. Interestingly, SIN1
induced a high enhance of p53-3NT expression in both wt and
unfolded p53 conformation in comparison with untreated. Uric
acid co-treatment expressed high levels of wt p53-3NT isoform,
due probably to the high immunoprecipitated PAb1620 positive
p53 isoform. At variance unfolded p53-3NT isoform was very low
when SIN-1 was co-added with uric acid (fig. 7C). These data
confirmed that nitration on tyrosine residues of p53 molecule is
responsible of protein conformational changes towards an
unfolded phenotype.
Discussion
In this study we demonstrated a correlation between oxidative
profile imbalance and the expression of a conformationally altered
p53 isoform in immortalized lymphocytes derived from two
peculiar cohorts of AD patients: sporadic cases with an early onset
(EOSAD) and a group of subjects harbouring AD mutations. This
last group was called ADmut, because only some of the patients
expressed clinical signs of AD at the time of blood withdrawal. An
advantage of examining these ADmut subjects is that every
alteration, found in them, can be associated with the pathogenesis
of the disease. Furthermore, EOSAD subjects, although they did
not harbour the most known AD-mutations, represented a very
homogeneous group. Oxidative profile was studied using two
parameters: 1) the measurement of typical oxidative stress
markers, such as HNE Michael adducts, as product of lipoperox-
idation, 3NT, derived from nitration to tyrosine residues and PC,
as a direct protein oxidation; 2) the quantification of antioxidant
capacity, carried out as the activity of SOD, GPx and GRD
enzymes.
Increased oxidative markers, such as HNE and 3-NT, were
observed in ADmut, but not in EOSAD lymphocytes. These data
are apparently in contrast with our previous observations on
sporadic AD brains. Increased oxidative markers were, in fact,
found in hippocampus and inferior parietal lobe of both sporadic
AD and MCI brains in comparison with control [38–40]. The
discrepancy between data reported in brain and peripheral cells of
EOSAD could be due to the higher susceptibility of CNS to free
radical damage, because brain has a high oxygen consumption
rate, abundant lipid content and a relative paucity of antioxidant
enzymes compared with other tissues [41]. It is presumable to
assume that, in periphery, oxidative stress takes more time to
develop because probably more efficiently endogenous and
exogenous (for example from the diet) antioxidants influence and
modulate ROS/RNS (reactive nitrogen species) generation.
Consistent with our observations, other studies failed to find
robust evidence of increased peripheral oxidative stress in sporadic
AD (SAD). Cecchi et al [42] have demonstrated that lipoperox-
idation in lymphoblast from patients affected by SAD was virtually
indistinguishable from the basal values of normal controls. On the
contrary more reproducible results were obtained on peripheral
cells derived from patients affected by familial AD. In fact
lymphoblasts derived from patients harbouring APP and PS1
mutation showed increased expression of oxidative markers [43].
At variance, an oxidative imbalance in EOSAD was demon-
strated by a reduced antioxidant capacity. SOD activity was
decreased in both ADmut and EOSAD when compared with
control, although the expression of SOD1 and SOD2 protein did
not change in the two pathological groups in comparison with
control. The fact that the expression of SOD enzymes does not
always correlate with their activity has been already reported in
AD animal models and patients [14,44]. It is noteworthy that
SOD enzyme is itself a target of oxidation, affecting its activity. At
this regard, chronic treatment with low concentration of 5 mM
H2O2 reduced SOD2 activity in HeLa cells. This event was
prevented by ascorbic acid and N-acetylcysteine, suggesting that
also SOD2 can be affected by the same ROS it neutralized [45].
Recently Bosco et al [46] demonstrated that oxidation of wt SOD1
protein induced conformational changes and decreased the
efficiency of this enzyme activity. Also GRD, but not GPX,
activity was decreased in EOSAD and ADmut lymphocytes.
EOSAD and ADmut further expressed a detectable amount of
unfolded p53 isoform. p53 conformational state was measured
with immunoprecipitation experiments using two specific confor-
mational antibodies, that recognized the wild type (PAb1620) and
altered (PAb240) tertiary structure. Unfolded p53, measured as the
ratio between PAb1620 and PAb240 immunoreactivity was found
statistically enhanced in immortalized lymphocytes derived from
EOSAD in comparison with control subjects. In addition, also the
majority of ADmut subjects, harbouring different mutations in the
APP, PS1, and PS2 genes, who were diagnosed AD at the time of
blood withdrawal, showed increased unfolded p53 in comparison
with control subjects. Lymphoblastoid cell lines obtained by
infecting peripheral blood mononuclear cells with the Epstein Barr
virus, have been documented to retain the cellular response of
freshly cells that they had at the moment of withdrawal [47,48].
Thus, some observations on these familiar cases can be made. PS2
Q228L mutation was found in a subject with MCI, with a MMSE
score of 28 that remained unaltered after 2 years. PS2Q228L
unfolded p53, measured as a ratio between PAb240/PAb1620, has
a value of 1,54 vs. mean control of about 0,560,08. One PS1
mutation, PS1 S170F, is a 9 years old child, whose parent,
harbouring the same mutation, is affected by the disease. The
child, of course, does not have any signs of pathology, however
child’s lymphocytes expressed an unfolded p53 value of 0,80 and
parent’s of 1,05. These results were consistent with those obtained
by independent scientific groups. We previously found higher
expression of PAb240 positive p53 isoform in fresh mononuclear
blood cells derived from sporadic AD patients and MCI patients,
who converted in AD followed two-year study, in comparison with
control subjects [18,49]. Zhou and Jia [50] demonstrated a p53-
mediated G1/S checkpoint dysfunction in lymphocytes from
sporadic AD, due to p53 conformational changes that affected its
tertiary structure. Furthermore, Serrano et al., [51] demonstrated
a significant increase of unfolded p53 in older AD transgenic mice
when compared with younger APPswe/PS1A246E animals and
wild-type counterparts of the same age. These latter data suggest
Unfolded p53 and Oxidative Stress
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e29789also a correlation between unfolded p53 and aging. At this regards
we indeed found a linear correlation between aging and unfolded
p53 in both control subjects and AD patients, with the highest
values of unfolded p53 in AD at each age examined [49].
A role of oxidative imbalance in p53 conformational changes
was suggested by the inverse correlation between unfolded p53
and SOD activity: a decrease of SOD activity was associated with
an increase of unfolded p53 expression. Furthermore, the SOD
inhibitor DETC, added to control lymphocytes for 24 h, was able
to recapitulate AD phenotype, inducing p53 conformational
changes towards a unfolded phenotype.
p53 belongs to a growing list of transcriptional factors, which
are subjected to redox modulation [52–54]. Reactive oxygen
intermediates (ROS) play at least two distinct roles in the p53
pathway. First, they are important activators of p53 through their
capacity to induce DNA strand break [17,55,56]. Second, they
regulate the DNA-binding activity of p53 by modulating the redox
state of a critical set of cysteines in the DNA-binding domain,
which in turn induces conformational changes [33,34,36]. The
duration and the degree of ROS signalling can influence one or
the other event.
When we measured the degree of HNE oxidation and nitration of
wild type and unfolded p53 isoforms, we preferentially found a
dramatic increase of p53-3NT in mutant conformation, both in
EOSAD and ADmut in comparison with control lymphocytes. The
effects of tyrosine nitration on p53 conformational state was also
demonstrated by the using of peroxynitrite-generating compound
SIN1. SIN1 induced the expression of PAb240 positive p53-3NT
isoform, while in untreated cells this peculiar isoform was virtually
absent. However also the p53 wt conformation was found nitrated in
a higherextent incells exposedtoSIN-1 thaninuntreated cells.This
is plausible since the p53 molecule contains 15 tyrosine residues, and
11 of them are inside the highly flexible DNA binding domain. In
accordancewith ourfinding,syntheticnitric oxide donors (such asS-
nitro-N-acetyl-penicilamine and S-nitrosoglutathione) have been
shown to induce a conformational switch of wild-type p53 to the
unfolded form, with loss of DNA-binding activity in vitro [57]. It is
well recognized that the nitration of tyrosine at the 3-position
sterically hinders the phosphorylation and also may change the
structure of proteins, thus making protein dysfunctional [58–60].
It is noteworthy that the young patient, who harboured a PS1
S170F mutation, expressed high levels of unfolded p53 and
unfolded nitrated p53, but low levels of oxidative markers
comparable to those found in control lymphocytes. Therefore,
we suggest that oxidation of p53 protein may be an early event in
establishing oxidative stress in periphery. In summary, we
demonstrated that, although in EOSAD patients oxidative stress
is not detectable in periphery when measured as oxidative
markers, the sign of an unbalanced redox state in these patients
is demonstrated by the effects that reactive nitrogen species (RNS)
have on p53 protein.
Materials and Methods
Subjects
Alzheimer’s disease patients and healthy subjects were enrolled
in the Department of Neurology, MSWiA Hospital, Warsaw,
Poland. The protocol of the study was approved by the Bioethical
Committee for Studies on Human Subjects at the Central Clinical
Hospital MSWiA in Warsaw, and is in compliance with the
National and European Union legislation and the Code of Ethical
Principles for Medical Research Involving Human Subjects of the
World Medical Association. Approval No 68/2008 and a written
consent was obtained from all subjects or, where appropriate, their
caregivers. The demographic and clinical informations as well the
mutations are reported in Table 1 and 2. Control subjects were
individuals with no clinical signs of neurological or psychiatric
diseases. All these subjects were examined by a senior neurologist or
geriatrician and diagnosisof dementia wasmade according to DSM-
IV and the NINCDS-ADRDA criteria. Dementia was diagnosed
based upon interview, objective and neurological examination,
cognitive evaluation, laboratory and radiological (CT Scan)
investigation. Cognitive status was quantified using the Mini Mental
State Examination (MMSE). AD patients represented both familial
(ADmut) and sporadic forms of the disease. ADmut patients were
carrying mutations in Presenilin 1 (PS1), Presenilin 2 (PS2) and
Amyloid Precursor Protein (APP) genes and showed classical early
onset of the disease (before their 50th). Patient with PS2 Q228L
mutation was diagnosed as having mild cognitive impairment (MCI)
and developed no AD features so far (5 years after first examination).
In ADmut group there were also a patient with PS1 S170F mutation
which caused very severe course of disease with the onset as early as
at 29 years, and her 9 years old healthy child. Because these groups
ofsubjectsharboringADmutationswerenotallaffectedbyAD,they
were named ADmut. On the other hand, patients with sporadic AD
were not typical SAD cases. Despite they bear no mutations in PS1
and PS2 and APP genes, onset of the disease was at early 50th or
evenbelowcomparingtothe‘‘classical’’SADswiththeonsetover65
years of age. Majority of those patients were also not bearing ApoE4
allele which is considered to be an AD risk factor (data not shown).
We called that group an Early Onset Sporadic Alzheimer’s Disease
(EOSAD) patients.
Cell cultures
Immortalized B lymphocytes derived from enrolled patients (see
above Bioethical Committee and confirmation of written inform
consent) were used [61]. Cell cultures were grown in RPMI
supplemented with 10% FBS, 2% of glutamine and 1% HEPES
(all from Sigma-Aldrich, Steinheim, Germany). As demonstrated
by Bartolome et al.[47] and Munoz et al. [48], immortalized
lymphoblast cell lines retained the cellular response of freshly cells.
Western blot analysis
Cells were lysed in buffer containing 10 mM Tris, pH 7.6;
140 mM NaCl; and 0.5 % NP40 including protease inhibitors.
After incubation for 20 min on ice, cell debris was cleared by
centrifugation. Protein content was determined by a conventional
method (BCA protein assay Kit, Pierce, Rockford, IL). Thirty
micrograms of protein extracts were electrophoresed separated on
12% SDS-PAGE, and transferred to nitrocellulose membrane
(Amersham-GE Life Sciences Healthcare, Milan, Italy). Filters
Table 1. Demographic and clinical characteristic of the
subjects enrolled in the study.
EOSAD ADmut CTRL
N (M;F) 9 (5; 5) 9 (5; 4) 9 (6; 3)
mean age ± SD 64654 4 696 5 62
Age of onset 54654 2 68-
MMSE 12,4691 1 , 2 68,2 27,862,9
Abbreviations: EOSAD, early onset sporadic AD; ADmut, familial AD; CTR,
control; M, male; F, female; LOI, length of illness; MMSE, Mini Mental State
Examination; N, number of individuals.
Values are expressed as mean 6 SD.
doi:10.1371/journal.pone.0029789.t001
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antibodies in 5% non-fat dried milk (Euroclone CELBIO, Milan,
Italy). The antibodies used for this study were: antibodies that
recognize the two isoforms of Superoxide Dismutase, Cu-Zn
Superoxide Dismutase (anti-SOD1, 1:400 dilution, Santa Cruz
Biotechnology Inc., Heidelberg, Germany), and Mn-Superoxide
Dismutase (anti-SOD2, 1:300 dilution, Sigma-Aldrich, St Louis,
MO, USA), and anti-a-tubulin antibody (1:1.500 dilution, Sigma-
Aldrich, St Louis, MO, USA). The secondary antibodies (Dako,
Glostrup, Denmark) and a chemiluminescence blotting substrate
kit (Amersham-GE Life Sciences Healthcare, Milan, Italy) were
used for immunodetection. Evaluation of immunoreactivity was
performed on immunoblots by densitometric analysis using Scion
Image (PC version of Macintosh-compatible NIH Image) software.
Measurement of protein carbonyls
Briefly, samples (5 mg of proteins) were derivatized with 10 ml
10 mM 2,4-dinitrophenylhydrazine (DNPH) (from OxyBlot
tm
Protein oxidation Detection Kit, Chemicon-Millipore, Billerica,
MA, USA), in the presence of 5 ml of 12% sodium dodecyl sulfate
for 20 min at room temperature (23uC). The samples were then
neutralized with 7.5 ml of the neutralization solution (2 M Tris in
30% glycerol). Derivatized protein samples were then blotted onto
a nitrocellulose membrane with a dot-blot apparatus. The
membrane was blocked with a solution of 5% non-fat dried milk
in Tris-buffered saline (TBS) solution, and followed by incubation
with rabbit polyclonal anti-DNPH antibody (1:100 dilution, from
OxyBlot
tm Protein oxidation Detection Kit, Chemicon-Millipore,
Billerica, MA, USA) as the primary antibody for 1 h at room
temperature. After washing the membrane with TBS buffer, it was
further incubated with HRP-conjugated goat anti-rabbit antibody
(1:300 dilution, from OxyBlot
tm Protein oxidation Detection Kit,
Chemicon-Millipore, Billerica, MA, USA) as the secondary
antibody for 1 h at room temperature. Blots were developed
using chemiluminescence blotting substrate kit (Amersham-GE
Life Sciences Healthcare, Milan, Italy), scanned with Adobe
Photoshop, and quantified using Scion Image (PC version of
Macintosh-compatible NIH Image) software. Non-specific binding
of the primary or secondary antibodies was found.
Measurement of 3-nitrotyrosine (3-NT)
The Nitro-Tyrosine content was determined immunochemically
as previously described [62]. Briefly, samples were incubated with
Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma base,
pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) for 20 min.
Protein (5 mg) was then blotted onto the nitrocellulose paper using
the slot-blot apparatus and immunochemical methods as described
above for protein carbonyls. The primary anti-3NT antibody
(Sigma-Aldrich, St Louis, MO, USA) diluted 1:1000, was
incubated at 4uC over night, followed by 3 hours at room
temperature and then HRP-conjugated goat anti-rabbit antibody
(1:1500 dilution, Dako, Glostrup, Denmark) at room temperature
for 2 hours was used for detection. Blots were then scanned by
Adobe Photoshop program, and densitometric analysis of bands in
images of the blots was used to calculate levels of 3-NT.
Measurement of 4-hydroxynonenal (HNE)
Assay was performed as previously described [63]. Briefly, 10 ml
of sample were incubated with 10 ml of Laemmli buffer containing
0.125 M Tris base pH 6.8, 4% (v/v) SDS, and 20% (v/v) glycerol.
The resulting sample (5 mg) was loaded per well in the slot blot
apparatus containing a nitrocellulose membrane under vacuum
pressure. The membrane was blocked with a solution of 5% non-
fat dried milk in Tris-buffered saline (TBS) solution and incubated
with a 1:200 dilution of anti-HNE polyclonal antibody (Alpha
Diagnostic International Inc., San Antonio, Texas 78244 USA) at
4uC over night and 3 hours at room temperature. An anti-rabbit
IgG alkaline phosphatase secondary antibody (Dako, Glostrup,
Denmark) was diluted 1:1500 in a solution of 5% non-fat dried
milk in Tris-buffered saline (TBS) solution buffer and added to the
membrane for 2 hours at room temperature. Quantitative analysis
was performed with Scion Image.
Antioxidant enzyme activity
SOD activity was performed using a buffer (G buffer) that
contained 0.05 M glycine (Sigma-Aldrich, St Louis, MO, USA,
0.1 M NaOH (Sigma-Aldrich, St Louis, MO, USA) and 0.1 M
NaCl (Sigma-Aldrich, St Louis, MO, USA), pH 10.3, and
epinephrine. (Sigma-Aldrich, St Louis, MO, USA).The reaction
was monitored in a 96-well plate reader by measuring the decrease
of absorbance at 480 nm.
GPx activity was measured by using a reaction mixture
consisting of 0.2 mM H2O2, 1.0 mM GSH, 0.14 U of glutathione
reductase (GRD), 1.5 mM NADPH, 1.0 mM sodium azide, and
0.1 M phosphate buffer (pH 7.4) and 1 mg/ml of supernatant
protein [64]. The changes in absorbance were recorded at 340 nm
in a 96-well microtiter plate.
GRD activity was carried out by using a reaction mixture
consisting of 0.1 M phosphate buffer (pH 7.6), 0.5 mM EDTA,
1.0 mM oxidized glutathione, 0.1 mM NADPH, and 10 ml PMS
in a total volume of 200 ml [65]. The enzyme activity was assayed
in a 96-well plate reader by measuring the disappearance of
NADPH at 340 nm.
Measurement of ROS/RNS generation
Intracellular ROS levels were measured using the fluorescent
dye 29,79-dichlorodihydrofluorescein diacetate (H2DCF-DA) (Mo-
lecular Probes), a nonpolar compound that is converted into a
nonfluorescent polar derivative (H2DCF) by cellular esterases after
incorporation into cells. H2DCF is membrane permeable and is
rapidly oxidized to the highly fluorescent 29,79-DCF (DCF) in the
presence of intracellular ROS [66]. For the experiments, B
lymphocytes were washed in Hanks’ Balanced Salt Solution
(HBSS, GIBCO) and then incubated in nitrogen-saturated HBSS
with 20 mMH 2DCF-DA dissolved in DMSO for 30 minutes at
37uC 5%CO2. After washing twice in HBSS, intracellular DCF
Table 2. Type of mutations, age of onset, and age of ADmut
patients.
Mutations Age of onset Age
PS1 H163R 50 59
PS2 Q228L 60 67
PS1 M139V 40 46
APP T714A 44 51
PS1 P117R 36 42
PS1 I213F 33 41
PS1 S170F 29 34
PS1 S170F 9
PS1 L153V ,40 41
Abbreviations: ADmut, familial AD, PS1, presenilin 1, PS2, presenilin 2, APP,
Amyloid Precursor Protein.
doi:10.1371/journal.pone.0029789.t002
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evaluated by flow cytometry.
Analysis of p53 conformational state
p53 conformational state was analysed by immunopreciptation
experiment, and Enzyme-linked Immunosorbent assay (ELISA)
assay, using the anti-p53 antibodies, PAb 1620 and PAb 240. In
particular, cells were lysed in immunoprecipitation buffer (10 mM
Tris, pH 7.6; 140 mM NaCl; and 0.5% NP40 including protease
inhibitors) for 20 min on ice, and cell debris was cleared by
centrifugation. Protein content was determined by a conventional
method (BCA protein assay Kit, Pierce, Rockford, IL). Before
immunoprecipitation experiments, an aliquot of 10 mg of protein
extracts from each individual sample were processed for Western
blot analysis and probed with anti-b tubulin antibody to validate
protein content measurements (data not shown). Based on the
previous results, one hundred micrograms of protein extracts were
used for immunoprecipitation experiments, performed in a volume
of 500 ml. To prevent non-specific binding, the supernatant of
immunoprecipitated samples was pre-cleared with 10% (w/v)
protein A/G (50 ml) (Santa Cruz Biotechnology Inc., Heidelberg,
Germany) for 20 min on ice, followed by centrifugation. For
immunoprecipitation of p53, 1 mg of the conformation-specific
antibodies PAb1620 (wild-type specific) (Calbiochem, EMB Biosci-
ence, La Jolla, CA, USA), PAb240 (mutant specific) (Neomarkers-
Lab Vision, Fremont, CA, USA) or PAbBP53.12 (Neomarkers-Lab
Vision,Fremont,CA,USA)(recognizingboth wild-typeandmutant
p53) were added to the samples and incubated overnight at 4uC.
Immuno complexes were collected by using protein A/G
suspension and washed five times with immunopecipitation buffer.
Immunoprecipitated p53 was recovered by resuspending the pellets
in Laemmli sample buffer. Western blot analysis was performed
using as primary antibodies: polyclonal anti-p53 antibody CM1
(Novocastra, Newcastle, UK), polyclonal anti-p53 antibody R19
(Santa Cruz Biotechnology Inc., Heidelberg, Germany), polyclonal
anti-HNE and polyclonal anti-3NT antibodies.
For ELISA assay 70 mg of non-denaturated protein extracts
were diluted in PBS 16 pH 7.4 and coated on the ELISA
microplate overnight at 4uC. The next day plates were saturated
with 100 ml of Blocking Solution (PBS 16pH 7.4–0,1% TWEEN
20 – 3% BSA) for each well and incubated for 1 h at RT, followed
by 2 h incubated at 37uC with anti-p53 Pab 240 antibody (0.5 mg/
ml). After washing with PBST, 0.1 mg/ml secondary anti-mouse
antibody conjugated with peroxidase was incubated in each well
for 1 h at RT. Finally, 100 ml of TMB (3,3,5,5-tetramethylbenzi-
dine) substrate is added and the reaction is stopped with 100 mlo f
sulphuric acid 2 M. Optical density (OD) is measured using a
microplate reader with a wavelength of 450 nm. Data was
expressed as the mean 6 SE of at least three experiments,
performed in triplicate.
Transactivation assay
Transient transfections were performed in 6 multi well culture
plates; for each well 7610
5 cells were seeded in medium without
FBS, antibiotics and with 1% L-glutamine. For transactivation
assay cells from control, SAD and FAD subjects were transfected
with the p53-target promoter AIP1-luciferase reporter plasmid
(kindly provided by H. Arakawa, National Cancer Center, Tokyo,
Japan), by using the transfection reagent LTX (Invitrogen
Carlsbad, CA) according to the manufacturer’s instructions.
AIP1-luciferase reporter construct plasmid DNA was co-transfect-
ed with pRL-TK Renilla luciferase expressing vector to measure
transfection efficiency (Promega, Madison, WI). Eighteen hours
later the cells were incubated with 50 mM doxorubicin for 24 h
before luciferase activity was assayed. The cells were then lysed
with Passive Lysis Buffer 16 provided by Dual-Luciferase
Reporter Assay System following the manufacturer’s specifications
(Promega, Madison, WI). Luminescence was measured employing
a 20/20n Luminometer with 10 sec of integration (Turner
BioSystems, Sunnyvale, CA). At least six independent experiments
were performed.
Statistical evaluation
Results are given as mean 6 standard error mean values.
Statistical significance of differences was determined by mean
values of the one way ANOVA, followed by the Bonferroni test.
Bartlett’s test was also performed. Significance was accepted for a
p,0.05.
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